Results 31 to 40 of about 96,164 (192)

Steatohepatitis in Children with Obesity

Вопросы современной педиатрии, 2021
The article discusses the issues of steatohepatitis development, diagnosis, and management in children. Steatohepatitis is one of the forms of non-alcoholic fatty liver disease diagnosed in 12–26% of children with obesity.
Alexander A. Zvyagin, Natalya Yu. Fateeva, Timofey V. Chubarov, Olga A. Zhdanova   +3 more
doaj   +1 more source

ST-segment elevation myocardial infarction in the presence of metabolic-associated fatty liver disease

Российский кардиологический журнал, 2023
Aim. To assess the characteristics of ST-segment elevation myocardial infarction (STEMI) in patients with metabolic syndrome (MS) in the presence and absence of metabolic-associated fatty liver disease (MAFLD).Material and methods.
V. A. Tretyakova, O. V. Ermilov, P. K. Alferov, V. Yu. Chernyavskaya, D. I. Pisankina, A. Yu. Tretyakov   +5 more
doaj   +1 more source

Insulin-like Growth Factor Binding Proteins and Cellular Senescence Are Involved in the Progression of Non-Alcoholic Fatty Liver Disease and Fibrosis in a Mouse Model

Medicina
Background and Objectives: Non-alcoholic fatty liver disease (NAFLD) is highly prevalent worldwide. It progresses from simple steatosis to non-alcoholic steatohepatitis (NASH).
Carolina Guzmán, Miriam G. Bautista-Ubaldo, Adriana Campos-Espinosa, Ivette I. Romero-Bello, Ángel Daniel Santana-Vargas, Gabriela Gutierrez-Reyes   +5 more
doaj   +1 more source

Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis[S]

Journal of Lipid Research, 2016
The accumulation of lipids is a histologic and biochemical hallmark of obesity-associated nonalcoholic fatty liver disease (NAFLD). A subset of NALFD patients develops progressive liver disease, termed nonalcoholic steatohepatitis, which is characterized
Petra Hirsova, Samar H. Ibrabim, Gregory J. Gores, Harmeet Malhi   +3 more
doaj   +1 more source

Pathogenesis of Nonalcoholic Steatohepatitis [PDF]

Gastroenterology, 2016
Nonalcoholic steatohepatitis (NASH) is a necro-inflammatory response that ensues when hepatocytes are injured by lipids (lipotoxicity). NASH is a potential outcome of nonalcoholic fatty liver (NAFL), a condition that occurs when lipids accumulate in hepatocytes. NASH may be reversible, but it can also result in cirrhosis and primary liver cancer.
Mariana Verdelho, Machado, Anna Mae, Diehl   +1 more
openaire   +2 more sources

Chemerin Overexpression in the Liver Protects against Inflammation in Experimental Non-Alcoholic Steatohepatitis [PDF]

, 2022
Rebekka Pohl, Susanne Feder, Elisabeth M. Haberl, Lisa Rein‐Fischboeck, Thomas S. Weiß, Marlen Spirk, Astrid Bruckmann, Nichole McMullen, Christopher J. Sinal, Christa Buechler   +9 more
openalex   +1 more source

Electro-acupuncture reduced steatosis on MRI-PDFF in patients with non-alcoholic steatohepatitis: a randomized controlled pilot clinical trial [PDF]

, 2023
Jingjie Zhao, Qianyi Wang, Xinyu Zhao, Lina Wu, Juanjuan Li, Wen Zhang, Shuai Xu, Chaoru Han, Yi Du, Xiaofei Tong, Weijia Duan, Di Cao, Hao Ren, Xinyan Zhao, Xiaojuan Ou, Jidong Jia, Hong You   +16 more
openalex   +1 more source

Chemotherapy-associated steatohepatitis

Annals of Hepatology, 2020
Some drugs may induce hepatotoxic lesions, such as steatosis or steatohepatitis found in Non-Alcoholic Fatty Liver Disease (NAFLD). Among these drugs there are some anti-tumoral molecules, such as methotrexate, 5-fluorouracil, irinotecan, tamoxifen and l-asparaginase. The hepatotoxic phenotype developed from treatment with such drugs is known as "CASH"
Meunier, Lucy, Larrey, Dominique
openaire   +4 more sources

Lymph Node Adiposity and Metabolic Dysfunction-Associated Steatotic Liver Disease

Biomedicines
Objective: Metabolic dysfunction-associated steatotic liver disease (MASLD), previously known as the most common chronic liver disease, is soon to be the leading indication for liver transplantation; however, the diagnosis may remain occult for decades ...
Jessica M. Rubino, Natalie Yanzi Ring, Krishna Patel, Xiaoqing Xia, Todd A. MacKenzie, Roberta M. diFlorio-Alexander   +5 more
doaj   +1 more source

Drug-Induced Steatohepatitis [PDF]

Clinics in Liver Disease, 2013
Nonalcoholic fatty liver disease (NAFLD) is currently the most common cause of chronic liver disease in the United States. The term NALFD was first used by Ludwig in 1980 to describe the presence of hepatic steatosis and steatohepatitis in a series of patients with no identifiable cause.
Vaishali, Patel, Arun J, Sanyal
openaire   +2 more sources